Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is Corbus Pharmaceuticals Holdings (CRBP) Stock Down -11.96% Today?

Why Is Corbus Pharmaceuticals Holdings (CRBP) Stock Down -11.96% Today?

Key Takeaways

  • CRBP shares fell 11.96% to $2.65, extending a two-day rout that has erased roughly 22% of the company's value.
  • The primary driver is the market's downbeat interpretation of the CANYON-1 Phase 1b obesity data presented at ObesityWeek 2026, which showed 5% mean weight loss at 12 weeks on the 60 mg dose — real efficacy, but below the bar set by injectables and rival oral candidates.
  • Secondary pressure came from a cluster of post-earnings analyst price-target cuts, including RBC Capital ($36 to $33), Mizuho ($24 to $23) and Wedbush ($30 to $27), all of which kept bullish ratings.
  • No fresh company release or data readout accompanied today's decline; a scheduled fireside chat at the Jefferies Global Healthcare Conference delivered no new clinical information.
  • Small-cap biotechnology remains under distribution pressure, with financing-dependent names bearing the brunt of the risk-off tone.
  • News Significance Score: 28/100 — Modest, largely digested news combined with a move that has recurred repeatedly in recent sessions.
  • Traders are watching for the next CRB-701 update, any capital raise, and whether the $2.81 area holds as support.
  • For deeper detail on Price Targets, Earnings and Forecast, explore Tickeron's dedicated pages for the ticker.
  • Investors can also review Tickeron's curated Trending AI Robots to see which automated strategies are performing best in the current tape.

Opening Summary

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage Massachusetts-based biotech developing sutantatug envedotin (CRB-701), a Nectin-4 antibody-drug conjugate for oropharyngeal and cervical cancers, and CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. In today's session the stock is trading at $2.65, down 11.96% from the prior close of $3.01, and has printed a fresh 52-week low of $2.64. No new press release, filing or clinical disclosure explains the move. Instead, the decline extends a selloff that began after the company's ObesityWeek 2026 poster on CRB-913 and accelerated through a series of analyst price-target revisions following third-quarter results.

The Obesity Data Did Not Clear the Bar

The central narrative remains the CANYON-1 Phase 1b readout. Corbus reported statistically significant mean weight loss of 5% at 12 weeks on the 60 mg dose, with no plateau, alongside reductions in waist circumference and BMI and fewer gastrointestinal adverse events than marketed oral GLP-1 therapies. The clinical signal is genuine. The valuation response was not: investors judged 5% at three months as insufficient to differentiate CRB-913 against injectable incretins or against oral programmes from far larger competitors. Because the obesity asset is a major component of the equity story alongside the oncology pipeline, that reassessment has a leveraged effect on the share price.

Analyst Revisions Reset Expectations

The Q3 report on November 10 showed a net loss of $37.8 million, or $1.81 per share, well wider than consensus, driven partly by a $15 million CSPC licensing milestone. Corbus closed the quarter with $115.3 million in cash and guided that runway extends into 2028. Revenue was zero, as expected for a clinical-stage company. The wider loss triggered a wave of target cuts — RBC Capital to $33, Mizuho to $23, Wedbush to $27, and a lowered full-year loss estimate from H.C. Wainwright — each paired with a retained Buy or Outperform rating. Lower targets do not change the fundamental case, but they do trim the ceiling that had supported the stock's November rally.

The Jefferies Appearance Added Nothing New

Management took part in a fireside chat at the Jefferies Global Healthcare Conference this morning. Commentary covered TEMPO-1 registrational trial design, the competitive position of sutantatotug envedotin against Padcev in Nectin-4, and encouraging key-opinion-leader feedback from ObesityWeek. No incremental data were disclosed. With the catalysts exhaustively discussed and the next major readout — first-line CRB-701 combination data — not expected before early 2027, the path of least resistance has been lower.

Market Context and Trading Activity

Volume has not been especially heavy relative to the stock's turnover history, with recent sessions running below the roughly 1.1 million-share average, a pattern that magnifies price movement in a name with a market capitalization near $55 million. The move is consistent with the broader retreat in small-cap biotechnology, where financing-dependent, pre-revenue companies are sold first when risk appetite contracts. CRBP has now broken decisively below its prior 52-week floor of $2.81 and sits far beneath its 50-day and 200-day moving averages, a configuration that tends to invite momentum-driven selling.

News Significance Score

The score runs from 0, meaning no meaningful news and a price move normal for the stock, to 100, meaning transformative news and an extreme, rare move. CRBP earns 28 out of 100. The verified news is real but moderate and no longer fresh: an obesity dataset that disappointed relative to competitive benchmarks, a wider-than-expected quarterly loss, and several target-price reductions. Judged against a company of this size, none of these is transformative.

The price move was meaningful but not extraordinary. At 11.96%, today's decline is roughly 2.9 times the stock's typical absolute daily move of about 4.2% over the past 60 sessions, and a move of this size or larger has occurred six times in that window. Strong news and an unusual move are both required for a high score; here, modest news and a familiar magnitude combine to produce a low reading.

What Comes Next for CRBP

Attention now shifts to execution on two fronts. On oncology, investors will track enrollment in the TEMPO-1 registrational study of sutantatug envedotin in second-line oropharyngeal cancer and the timing of first-line combination data expected in early 2027. On obesity, the company has signalled plans to engage regulators on a development path for CRB-913 and to evaluate combination use with GLP-1 therapy, with longer-duration weight-loss data the key variable. Fourth-quarter results and the company's year-end cash position will also matter, since a widening loss profile can revive dilution concerns even with runway into 2028. Management appearances at the Evercore Healthcare Conference on December 1 and any subsequent financing activity are near-term items to monitor. Analysts remain overwhelmingly constructive on ratings and targets, but that consensus is precisely what has been under pressure.

Trending AI Robots

Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, allowing users to compare approaches side by side. In a tape as volatile as small-cap biotech, seeing which automated strategies are working right now can sharpen a trader's own process. Explore the page and review the current leaders.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRBP

Contributor

Dem Sem's AvatarDem Sem|Expert

CRBP's Indicator enters downward trend

The Aroon Indicator for CRBP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 288 similar instances where the Aroon Indicator formed such a pattern. In 262 of the 288 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for CRBP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for CRBP just turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

Following a +13.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 226 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.592). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of drug development services

Industry Biotechnology

Industry
Biotechnology
Address
500 River Ridge Drive
Phone
+1 617 963-0100
Employees
36
Web
https://www.corbuspharma.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.